APTOF — Aptose Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Aptose Biosciences On Feb 29, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Aptose Announces Pricing Of $8.4 Million Public Offering And A Concurrent $4 Million Private Placement With Hanmi Pharmaceutical
Brief: Aptose Reports Complete Response Data From Ongoing Aptivate International Phase 1/2 Study Of Tuspetinib
Brief: Aptose Biosciences Files For Offering 4.1 Million Common Shares, Together With Pre-Funded Warrants And/Or Warrants To Purchase Offered Shares
U.S. STOCKS ON THE MOVE-Moderna, Aldeyra Therapeutics, Colgate-Palmolive
Brief: Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
Brief: Aptose Biosciences Inc Files For Resale Of Up To 1.26 mln Common Shares By Selling Shareholder - SEC Filing
Brief: Aptose Presents Highlights From Clinical Update
Brief: Aptose Biosciences Provides Update On Reverse Stock Split
Brief: Aptose Enters Into $25 Million Committed Equity Facility
Brief: Aptose Biosciences Approved Reverse Stock Split On Basis Of 15 Common Shares For One Common Share
Brief: Aptose Reports Results For The First Quarter 2023
Brief: Aptose Biosciences Inc Reports Quarterly Loss Per Share Of $0.11
Brief: Aptose Reports Immaterial Financial Exposure To Silicon Valley Bank
Brief: Aptose Starts Dosing Of Tuspetinib In Patients With Acute Myeloid Leukemia
Brief: Aptose Biosciences Inc Says Entered Into An Equity Distribution Agreement With Jonestrading Institutional Services
Brief: Aptose Announces Updated Clinical Responses, Breadth Of Activity, And Safety Across Four Dose Levels Of Tuspetinib In Difficult-To-Treat Acute Myeloid Leukemia Populations
Brief: Aptose Biosciences Says On Nov 18, Co Notified Piper Sandler, Canaccord Genuity To Terminate An Equity Distribution Agreement Dated May 5, 2020
Brief: Aptose Treats First Patient With Continuous Dosing Of New “G3” Formulation Of Luxeptinib